What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron, Aleniglipron, Aleniglipron, Aleniglipron for obesity, overweight, or chronic weight management.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment. At the end of the study (after completing 36 weeks of treatment), participants will be offered to continue with an open-label extension (OLE) where they will receive aleniglipron for an additional 36 weeks.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Signed informed consent * BMI ≥30 kg/m2 or BMI ≥27.0 kg/m2 and previous/current diagnosis of ≥ 1 obesity related comorbidity Exclusion Criteria: * Previous documented diagnosis of diabetes mellitus. * Self-reported change in body weight \>5% within 3 months before Screening * Body weight ≤80 kg at Screening * Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)
Study sites by state
Arizona
- ACCESS Research Site — Phoenix
California
- ACCESS Research Site — Anaheim
- ACCESS Research Site — Los Angeles
- ACCESS Research Site — Montclair
- ACCESS Research Site — Rancho Cucamonga
- ACCESS Research Site — Sacramento
- ACCESS Research Site — Spring Valley
Hawaii
- ACCESS Research Site — Honolulu
Illinois
- ACCESS Research Site — Chicago
- ACCESS Research Site — Chicago
- ACCESS Research Site — Evanston
Indiana
- ACCESS Research Site — Muncie
- ACCESS Research Site — Valparaiso
Iowa
- ACCESS Research Site — West Des Moines
Louisiana
- ACCESS Research Site — Baton Rouge
Minnesota
- ACCESS Research Site — Richfield
Missouri
- ACCESS Research Site — City of Saint Peters
- ACCESS Research Site — Hazelwood
- ACCESS Research Site — Springfield
New York
- ACCESS Research Site — Albany
- ACCESS Research Site — Binghamton
- ACCESS Research Site — Brooklyn
- ACCESS Research Site — Rochester
North Carolina
- ACCESS Research Site — Wilmington
Ohio
- ACCESS Research Site — Cincinnati
Oklahoma
- ACCESS Research Site — Norman
Oregon
- ACCESS Research Site — Medford
Pennsylvania
- ACCESS Research Site — Pittsburgh
South Carolina
- ACCESS Research Site — Moncks Corner
Tennessee
- ACCESS Research Site — Chattanooga
Texas
- ACCESS Research Site — Austin
- ACCESS Research Site — Austin
- ACCESS Research Site — Dallas
- ACCESS Research Site — Dallas
- ACCESS Research Site — Mesquite
- ACCESS Research Site — Shavano Park
Utah
- ACCESS Research Site — West Jordan
Virginia
- ACCESS Research Site — Winchester
West Virginia
- ACCESS Research Site — Morgantown
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)